The Next Generation Cancer Diagnostics Market is expected to grow at a CAGR of 17.60% over the forecast period 2021-2027.
Increasing demand for preventive medicine and companion diagnostics is an important factor driving the market growth, and increasing cancer incidence and growing elderly population are key factors driving the next-generation cancer diagnostics market. In addition, technological advances in the machine will further create new opportunities for the next-generation cancer diagnostics market in the forecast period 2021-2027.
A full report of Next Generation Cancer Diagnostics Market available at https://www.orionmarketreports.com/next-generation-cancer-diagnostics-market/2070/
Next Generation Cancer Diagnostics Market: Segmentation
By Technology
• Next Generation Sequencing
• qPCR & Multiplexing
• Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
• Protein Microarrays
• DNA Microarrays
By Application
• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis
By Cancer Type
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Others
By Function
• Therapeutic Monitoring
• Companion Diagnostics
• Prognostics
• Cancer Screening
• Risk Analysis
Market Key Players
• Agilent Technologies, Inc.
• Biospherex LLC
• Cepheid
• F. Hoffmann-La Roche Ltd
• General Electric Co.
• Lunaphore Technologies S.A.
• QIAGEN N.V
• Thermo Fisher Scientific Inc.
• Abbott
• Koninklijke Philips N.V.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
